Key facts
- Abrus Bio’s last known valuation is $31.5M (Sep 2025).
- It has raised $19.5M; the latest was Early Stage VC ($15.0M) in Sep 2025.
- Notable investors include Paladin Capital Group, General Inception, Vensana Capital.
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Abrus Bio
- ·The full record, as it builds
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for Abrus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About Abrus Bio
The company is currently operating in Stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- San Diego, CA, United States
- Founded
- 2022
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Abrus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Abrus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Abrus Bio in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.